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Copyright © 2007 AHC Hypoxia inducible factor-1α (HIF-1α) predominantly determines the transcriptional activity of
HIF-1, which induces the certain genetic expressions to participate in the proliferation and
progression of the tumor. It is supposed that HIF-1α is also an extremely important factor in
cancer treatment. Based on the results of our recent analyses using ovarian tumors, which
indicated the close association of HIF-1α expression with the acquisition of malignancy and
the characterization of histology, we further investigated the possibility of a new strategy
of cancer therapy that targeted HIF-1α inhibition in the ovarian carcinoma. The cell line
HUOCA-II, which originates from the refractory ovarian clear cell adenocarcinoma, was
treated with rapamycin. The inhibitory effect of HIF-1α was analyzed by immunohistochem-
istry and western blotting. It was demonstrated that inhibition of HIF-1α and vascular endo-
thelial growth factor (VEGF) expressions would lead to the down-regulation of tumor cell
proliferation. Interestingly, there was little or no change in GLUT-1 expression by rapamycin
administration. Thus, the inhibition of GLUT-1 may also be a key for the new strategy of
cancer therapy as well as HIF-1α and VEGF.
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All normal and neoplastic tissues are thought to possess
a mechanism to survive in a hypoxic condition by modulat-
ing certain crucial genes. Among them is hypoxia inducible
factor-1 (HIF-1), which has been known as a key gene to
adapt cells to microenvironmental conditions by up-regula-
tion of transcription response to hypoxia [19] (Fig. 1). Thus,
throughout the HIF-1-mediated pathway, various hypoxia-
related factors (HRFs) represented by vascular endothelial
growth factor (VEGF) and glucose transporter-1 (GLUT-1)
are activated [17]. HIF-1 is a heterodimeric protein consist-
ing of an α subunit and a β subunit, both of which contain
a basic helix-loop-helix and PER-ARNT-SIM homology
domains. While HIF-1β is constitutively expressed in the
nucleus, HIF-1α is known to be overexpressed in accord-
ance with the hypoxic status. Under the non-hypoxic con-
dition, HIF-1α protein level is controlled by hydroxylation
mediated by prolyl hydroxylase, and subsequently modified
due to its binding to von Hippel-Lindau protein, finally lead-
ing to its degradation by the ubiquitin-proteasome system [8,
14]. The adaptation of tumors to the hypoxic condition by
efficient induction of HRFs is believed to contribute to their
aggressiveness or poor prognosis, because these tumors
achieve an increased resistance to chemotherapy and radio-
therapy [11].
Overexpression of HIF-1α could be involved as an
early event of carcinogenesis in breast and prostate cancer
[11]. There have been some positive links between the poor
clinical outcome or increased mortality and strong expres-
sion of HIF-1α [2–4, 21, 24]. In our study using ovarianFujita et al. 140
tumors, immunohistochemical HIF-1α expression tended to
be strengthened in adenocarcinomas compared to adenomas
and borderline tumors. As for the adenocarcinomas, interest-
ingly enough, the expression profiles of HIF-1α differed to
some extent among each of the histologic types [23]. That is,
the hypoxic status is expected to be closely related to the
histologic feature such as papillary or piling structure ac-
companied by little or no vascular stroma, which is more
commonly observed in the serous adenocarcinoma and
clear cell adenocarcinoma [23]. This phenomenon was also
satisfactorily explained by GLUT-1 overexpression in the
thyroid papillary carcinoma [22]. The quantitative analysis
of HIF-1 transcription activity using the ELISA technique
corresponded with the immunohistochemical profiles: the
highest value was noted in clear cell adenocarcinoma (data
not shown). Lee et al. also reported that the hypoxia may
change according to the histological type of ovarian cancer
and that high HIF-1α expression in the clear cell adeno-
carcinoma may confer chemoresistance [12]. Just recently,
Osada et al. suggested that nuclear expression of HIF-1α is
a determinant prognostic factor of the ovarian carcinomas
[16].
It should be noted that the interest in HIF-1 as a thera-
peutic target for malignant tumors has expanded exponen-
tially in the last two decades [18]. Because suppression of
HIF-1 could lead to a down-regulation of hypoxia-inducible
genes, several kinds of anti-neoplastic/anti-angiogenic
agents including nonsteroidal anti-inflammatory drugs have
been utilized in experimental or clinical trials to clarify how
effective they could be in the suppression of the activity and
accumulation of HIF-1α in some tumors [11]. Rapamycin, a
macrolide antibiotic, is expected to inhibit the mammalian
target of rapamycin (mTOR), which is a serine-threonine
kinase that functions downstream of the phosphoinositide-
3-kinase-related kinase family [18] (Fig. 1). The recently ex-
ploited analogs (derivatives) of rapamycin were applied to
experimental studies to investigate the efficacy as anti-tumor
drugs as well as that as immunosuppressive drugs [5]. The
analogs were also being clinically tested in patients with
some tumors [1]. Using the experimental models to test the
efficacy of rapamycin in ovarian cancer treatment, a sig-
nificant correlation between HIF-1α inhibition and VEGF
down-regulation or increase of apoptosis has been demon-
strated [9], and it was mentioned that rapamycin delays the
tumor onset and progression [13]. Additional effects were
found to be exerted when rapamycin is administered in com-
bination with paclitaxel [9] and tamoxifen [20].
Our study was preliminarily designed to clarify
whether the cell line from refractory ovarian cancer could
be suppressed by administration of rapamycin alone. The
cell line HUOCA-II, which was established from the recur-
rent ovarian clear cell adenocarcinoma after surgery and
chemotherapy, was cultured in Ham’s F-12 medium supple-
mented with 15% heat-inactivated fetal bovine serum (FBS;
Gibco BRL, Grant Island, NY) and penicillin-streptomycin
(Gibco BRL, Grant Island, NY) in a 5% CO2 incubator at
37°C. The cells treated with rapamycin (Sigma, St. Louis,
MO) at a density of 100 nM and 1 µM were cultured for
6 hours, and then collected to make samples for immuno-
histochemical and western blotting analyses (HIF-1α for
immunohistochemistry, clone H1α67, diluted at 1:60, Novus
Biologicals, Littleton, CO; HIF-1α for western blotting,
Fig. 1. HIF-1α up-regulation and ubiquitination pathway. Mammalian target of rapamycin (mTOR) is a serine-threonine kinase that functions
downstream of the phosphoinositide-3-kinase (PI3K) and AKT signaling cascade, and can be expected to be suppressed by certain agents such
as rapamycin. The suppression effect on mTOR leads to down-regulation of hypoxia-related factors represented by GLUT-1 and VEGF.HIF-1α Suppression by Rapamycin 141
polyclonal, diluted at 1:200, Santa Cruz Biotechnology,
Santa Cruz, CA; VEGF, polyclonal, diluted at 1:50, Santa
Cruz Biotechnology, Santa Cruz, CA; GLUT-1, polyclonal,
diluted at 1:50, Dako, Carpinteria, CA). The differences in
expression of HIF-1α, VEGF and GLUT-1 were semi-
quantitatively compared between rapamycin-treated cells
and non-treated cells. HIF-1α and VEGF expressions were
prominently inhibited in rapamycin-treated cells; the in-
hibition was found to be dependent on the concentration
of rapamycin. Interestingly, there was little or no change in
GLUT-1 expression (Figs. 2, 3). The proliferation activity
was evaluated by the labeling index of Ki-67 (clone MIB-
1, diluted at 1:50, Dako, Carpinteria, CA). Compared to
non-treated cells, the index tended to decrease with the
concentration-dependency as follows: non-treated, 31.7%;
100 nM, 27.2%; 1 µM, 22.4%.
The results of our study were basically in concordance
with those of recent studies in that HIF-1α expression and
VEGF expression are closely linked [9]. But, to our knowl-
edge, there have been no reports referring to the interaction
between HIF-1α and GLUT-1. We suppose that it may be
difficult to suppress GLUT-1 expression by using rapamycin
alone. GLUT-1 expression in ovarian tumors is considered
to be related to malignant transformation [6], tumor invasion
[10] and histological difference [23]. The overexpression of
GLUT-1 in ovarian adenocarcinoma is commonly observed
around areas which are far away from vascular vessels, sug-
gesting GLUT-1 being a reliable marker of ischemia [7, 23].
Namely, GLUT-1 is expected to be essential for the tumor
cells to survive especially in a severely hypoxic microenvi-
ronment in addition to HIF-1α. There has been only one
report that suggests the possibility of GLUT-1-targeted
anti-cancer therapy, which describes that the expression of
antisense GLUT-1 mRNA via gene therapy can be used as
a tool in the treatment of cancer [15]. Based on the hypothe-
sis that GLUT-1 is also a key gene of anti-cancer therapy as
Fig. 2. Immunohistochemical expressions of
HIF-1α (A, B), VEGF (C, D) and GLUT-1 (E,
F). A, C, E: non-treated (negative control), B,
D, F: rapamycin-treated at 1 µM. In the cells
treated with rapamycin, the positive reaction
was considerably attenuated or completely sup-
pressed for HIF-1α and VEGF, but no apparent
change in GLUT-1 expression was noted.Fujita et al. 142
well as HIF-1α, we are working on a study to clarify the
condition when more significant effects on tumor suppres-
sion by rapamycin can be achieved in vivo or in vitro in
combination with the certain chemotherapeutic agents.
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Fig. 3. Western blotting analysis. M: marker, 1: non-treated, 2:
rapamycin-treated at 100 nM, 3: rapamycin-treated at 1 µM. The
decrease in positive reaction of HIF-1α and VEGF showed a ten-
dency toward concentration-dependency, but GLUT-1 expression
was found to be unchangeable.